State of Tennessee Department of Treasury Sells 159,945 Shares of Pfizer Inc. (NYSE:PFE)

State of Tennessee Department of Treasury decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,070,607 shares of the biopharmaceutical company's stock after selling 159,945 shares during the quarter. State of Tennessee Department of Treasury's holdings in Pfizer were worth $54,933,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $32,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. UBS Group decreased their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Stock Up 0.4 %

NYSE:PFE opened at $22.13 on Monday. The company's 50 day moving average is $24.88 and its two-hundred day moving average is $26.15. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $125.50 billion, a PE ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.